GALMED Aktie

>GALMED Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: +1,0%

laufendes Jahr: 0%

>GALMED Aktie

Name:

GALMED PHARMACEUT.IS 1,80

Land:

Israel

Sektor:

Gesundheit

ISIN/ Wkn:

IL0011313900 / A1XFUX

Symbol/ Ticker:

GPH (Frankfurt) / GLMD (NASDAQ)

Kürzel:

FRA:GPH, ETR:GPH, GPH:GR, NASDAQ:GLMD

Index:

Webseite:

https://galmedpharma.com/

Profil:

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutic solutions in the healthcare industry, particularly focusing on liver diseases. Its primary aim is to addre..
>Volltext..

Marktkapitalisierung:

2.56 Mio. EUR

Unternehmenswert:

-14.05 Mio. EUR

Umsatz:

EBITDA:

-6.16 Mio. EUR

Nettogewinn:

-7.54 Mio. EUR

Gewinn je Aktie:

-3.05 EUR

Schulden:

Liquide Mittel:

2.98 Mio. EUR

Operativer Cashflow:

-5.49 Mio. EUR

Bargeldquote:

7.76

Umsatzwachstum:

Gewinnwachstum:

-37.57%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

GALMED

Letzte Datenerhebung:

04.04.26

>GALMED Kennzahlen

Aktien/ Unternehmen:

Aktien: 5.48 Mio. St.

Frei handelbar: 98.81%

Leerverk. Aktien: 0.26%

Rückkaufquote: -280.05%

Mitarbeiter: 6

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 0.15

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -40.91%

Eigenkaprendite: -46.34%

>GALMED Peer Group

Gesundheit

>GALMED Chart & Kurs - NASDAQ

>GALMED News

31.03.26 - 22:18	Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 (PR Newswire)
	TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that it has filed its Annual Report on......

30.01.26 - 22:33	Galmed Pharmaceuticals receives Nasdaq bid price deficiency notice (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.01.26 - 22:18	Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
	TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company received a letter from......

08.12.25 - 14:33	Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting (PR Newswire)
	Late Breaking Abstract titled "Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol and regorafenib" to be presented with a poster on December 9 at 3pm (HST). RAMAT-GAN,......

04.12.25 - 15:54	Galmed-Aktie legt nach Patent für MASH-Kombinationstherapie zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.12.25 - 14:33	Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals′ Rezdiffra (Resmetirom) for MASH (PR Newswire)
	The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July 2042. Aramchol is a first-in-class, Phase 3 ready, drug candidate, that......

01.12.25 - 17:30	Optimistischer CEO-Brief treibt Galmed-Aktie an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

01.12.25 - 14:33	Galmed Issues CEO Letter to Shareholders (PR Newswire)
	TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today issued a Letter to Shareholders from Allen......

26.11.25 - 14:42	Galmed GAAP EPS of -$0.33 beats by $0.21 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.11.25 - 14:33	Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
	TEL AVIV, Israel, Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, reports financial results for the three and nine......

18.11.25 - 14:33	Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine (PR Newswire)
	The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tablets The new unexpected PK profile allows for a once daily therapeutic regimen thus......

17.11.25 - 15:24	Galmed-Aktie schießt nach vielversprechenden Studienergebnissen zur Krebsbehandlung in die Höhe (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

17.11.25 - 14:36	Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro (PR Newswire)
	The top-line results from the study showed that the 3-drugs' synergistic effect has the potential as a new fixed-dose combination treatment, enhancing the effect of Bayer's top selling cancer drug, Stivarga® (regorafenib); such combination could potentially become a life-cycle IP strategy......

25.08.25 - 13:33	Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value (PR Newswire)
	An amendment to the Company's Articles of Association to increase the authorized share capital from 50,000,000 ordinary shares to 900,000,000 ordinary shares was approved at the Company's Special General Meeting of shareholders held on August 15, 2025 The Company is initially planning to......

18.08.25 - 23:33	Galmed files to sell 7.5M shares of common stock for holders (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.05.25 - 14:01	Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH (PR Newswire)
	Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart......

22.05.25 - 14:12	Galmed GAAP EPS of -$0.62 beats by $0.27 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.25 - 13:33	Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer′s Regorafenib Effect in GI Cancer Models (PR Newswire)
	Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models. The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.......

28.04.25 - 14:03	Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation (PR Newswire)
	The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). The new formulation is expected to offer alternatives to both approved......

17.04.25 - 14:33	Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers (PR Newswire)
	Galmed Pharmaceuticals (Nasdaq: GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. Aramchol, a first-in-class SCD1 inhibitor, will be studied in......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram